Novartis scores a quick FDA OK for its new cancer drug Lutathera, picked up in $4B buyout
It didn’t take long for Novartis’ $NVS $4 billion acquisition of Advanced Accelerator Applications to pay off. The FDA has provided its stamp of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
